VIVO / Meridian Bioscience, Inc.'s (VIVO) CEO Jack Kenny on Q1 2022 Results - Earnings Call Transcript

After launching three new products and posting a second quarter of rising EPS growth, medical devices leader Merit Medical Systems is probing a new bu more_horizontal

VIVO stock is a hot topic on Wall Street today, not just because Meridian Biosciences released a fiscal update, but also due to takeover news. The pos more_horizontal

100% technical buy signals. 8 new highs and up 15.79% in the last month. more_horizontal

CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and lif more_horizontal

Meridian Bioscience Inc (NASDAQ: VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segmen more_horizontal

Meridian Bioscience, Inc. (NASDAQ:VIVO ) Q2 2022 Earnings Conference Call May 6, 2022 10:00 AM ET Corporate Participants Charlie Wood - Vice President more_horizontal

Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound s more_horizontal

Meridian Bioscience (VIVO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared more_horizontal